Share chart Bluebird Bio
Extended chart
Simple chart
About Bluebird Bio
Bluebird bio, Inc., биотехнологическая компания, исследует, разрабатывает и коммерциализирует трансформирующие генные методы лечения тяжелых генетических заболеваний и рака. Его продукты-кандидаты для лечения тяжелых генетических заболеваний включают betibeglogene autotemcel для лечения зависимой от переливания крови ß-талассемии; ЛентиГлобин для лечения серповидно-клеточной анемии; и эливальдоген аутотемцел для лечения церебральной адренолейкодистрофии. more details| IPO date | 2013-06-19 |
|---|---|
| ISIN | US09609G1004 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.bluebirdbio.com |
| Цена ао | 3.85 |
| Change price per day: | 0% (4.16) |
|---|---|
| Change price per week: | +0.4831% (4.14) |
| Change price per month: | +10.93% (3.75) |
| Change price per 3 month: | -46.67% (7.8) |
| Change price per half year: | -57.95% (9.892) |
| Change price per year: | -77.46% (18.456) |
| Change price per 3 year: | +27.22% (3.27) |
| Change price per 5 year: | -91.88% (51.2) |
| Change price per 10 year: | -90.83% (45.3875) |
| Change price per year to date: | -50.12% (8.34) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| State Street Corporation | 13865719 | 12.68 |
| Blackrock Inc. | 8983001 | 8.22 |
| Vanguard Group Inc | 8775379 | 8.03 |
| Granahan Investment Management LLC | 8077697 | 7.39 |
| Alyeska Investment Group, L.P. | 6912502 | 6.32 |
| Pictet Asset Management Holding SA | 5687334 | 5.2 |
| Norges Bank Investment Management | 3995600 | 3.65 |
| Millennium Management LLC | 3413612 | 3.12 |
| Palo Alto Investors Lp | 3333333 | 3.05 |
| Ghisallo Capital Management, LLC | 3150000 | 2.88 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Direxion Low Priced Stock ETF | 2.79 | 0 | 0.02 |
| Principal Healthcare Innovators ETF | 0.00822 | 618.5 | 0.8416 |
| Future Tech ETF | 0.00822 | 426.34 | 0.8416 |
| 0.94 | 348.28 | 0.57 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Andrew Obenshain | President, CEO & Director | 1.04M | 1974 (51 year) |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 654.97k | 1972 (53 years) |
| Ms. Andrea Walton | Chief People Officer | N/A | |
| Mr. Kasra Kasraian | Senior Vice President of Technical Development & Operations | N/A | |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | N/A | 1972 (53 years) |
| Jess Rowlands | Head of Corporate Communications | N/A | |
| Mr. Scott Shoemaker | Senior Vice President of Quality | N/A | |
| Mr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 696.24k | 1966 (59 years) |
| Ms. Sarah Alspach | Senior Vice President of External Affairs | N/A | |
| Mr. Oliver James Sterling III | CFO & Principal Accounting Officer |
Address: United States, Cambridge, 60 Binney Street - open in Google maps, open in Yandex maps
Website: http://www.bluebirdbio.com
Website: http://www.bluebirdbio.com
